IDEAYA Biosciences Inc

In a Stage 3 distribution environment following an early-July blow-off top, price has broken below the short-term EMAs and formed lower highs, signaling medium-term bearishness. With no mean-reversion eligibility and rejection at key moving averages, short-term conditions favor downside participation. We engage via Sell Now on rallies into the 9/21 EMA zone.

• ↑Initiation of Phase 1/2 IDE892 study targets MTAP-deleted pancreatic and lung cancers.
• ↑$1.1B in cash and marketable securities as of Sep 30, 2025 funds operations into 2030.
• ↓Negative earnings yield and weak profitability indicate ongoing losses.